ArticleFrontiers in oncology2025
Risk of hematological malignancies and anticipation in the families of patients with non-Hodgkin and Hodgkin lymphoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Familial lymphoma and genetic predisposition: an updated review.BMC medical genomics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Data on patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) with a family history of malignancy (FHM) and anticipation are limited. These patients provide an opportunity to study the responsible genes and clinical outcomes. There is no comprehensive report from the Middle East, where large family sizes and consanguineous marriages are common. Here, we report our observations. Methods: This was a retrospective, single-institution cohort study. Patients seen in the lymphoma clinics were comprehensively interviewed for FHM. Results: We interviewed 1,274 lymphoma patients for FHM: 591 (46.4%) with NHL and 683 (53.6%) with HL; 745 (58.5%) were men. The median age was 32 years. Consanguineous marriages were reported in 9.1% (parents) and 9.2% (patients). Among them, 524 (41.1%) patients had no FHM, whereas 750 (58.9%) had FHM. Patients reported a total of first-, second-, and third-degree relatives and 1,249 relatives with 1,263 malignancies. In total, 254 patients reported family members with hematological malignancy only (131, 10.3%) or hematological plus solid malignancies (123, 9.7%), while 496 (38.9%) reported only solid cancers. In total, 254 patients identified 305 affected relatives: NHL, 67 (22%); HL, 70 (23%); lymphoma not otherwise specified (NOS), 30 (9.8%); leukemia, 111 (36.4%); and other hematological malignancies, 27 (8.5%). Relationship pairs (n = 305) included parent/child (36), sibling/sibling (54), sibling/half-sibling (6), uncle/aunt or nephew/niece (46), grandparent/grandchild (14), and patient/cousin (59). These 305 disease pairs were: NHL/NHL, 39 (12.8%); NHL/lymphoma NOS, 17 (5.6%); NHL/HL, 66 (21.6%); NHL/leukemia, 47 (15.4%); NHL/others, 4 (1.3%); HL/HL, 51 (16.7%); HL/lymphoma NOS, 13 (4.3%); HL/leukemia, 64 (21%); and HL/others, 4 (1.3%). Anticipation data were available for 92 pairs (63.3%); earlier age at diagnosis in the first generation (58 years) versus the second generation (24 years, p=<no><</no> 0.001) was significant, even after correction for ascertainment bias. Conclusion: In patients with NHL and HL, FHM is common, and anticipation was observed. Future studies should explore the genetic basis of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.